Biogen Idec, Neurimmune Therapeutics in JV to develop alzheimer's treatments
November 20, 2007: 02:30 AM EST
Biogen Idec (NASDAQ:BIIB) and Neurimmune Therapeutics AG announced they have entered into an agreement for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimer's disease (AD).
The alliance will focus on the development of antibodies that bind to amyloid beta (A(beta)), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in AD patients. Currently there are no therapies for AD approved to slow or stop the progression of the disease.
Neurimmune will conduct research to identify potential therapeutic antibodies using the company's Reverse Translational Medicine (RTM) platform. Biogen Idec will be responsible for the development and commercialization of all products. Neurimmune could receive an aggregate of 380 mln usd in upfront and success-based milestone payments, as well as a royalty on net sales of any products. Link
In contrast to Biogen's dreams of another expensive antibody, there's evidence that a helpful agent for treating Alzheimer's disease can be found in the grocery store. However, getting it studied in a clinical trial may take some work as it's unlikely that it's possible to patent turmeric.
Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.
J Neurochem. 2007 Aug;102(4):1095-104.
Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients.
J Alzheimers Dis. 2006 Sep;10(1):1-7.
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
J Biol Chem. 2005 Feb 18;280(7):5892-901.
Note that the full paper of the last reference is available for free.